Articles related to HIV

Single-tablet regimen (STR) coverage under qualified health plans (QHPs) varies widely across the US. Although bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) coverage has grown over time, many QHPs in priority jurisdictions for the Ending the HIV Epidemic (EHE) have coinsurance requirements. Delay in QHP coverage and benefit design may hinder access to new antiretroviral treatment (ART) regimens.

Other than anterior cervical and occipital lymphadenopathy, the physical examination and vitals are unremarkable. The patient is also requesting HIV pre-exposure prophylaxis initiation. HIV testing negative. What’s the best management?

Sunlenca (lenacapavir), which comes in 300 mg tablets and a 463.5 mg/1.5 mL injection, provides doctors with a long-needed twice-yearly option for patients with complicated past treatment histories who would otherwise have few treatment options.

A trio of posters look at clinical effectiveness fostemsavir for multidrug-resistant patients, real-world efficacy of the dolutegravir/lamivudine combination as a switch strategy, and a newer drug in the pipeline, islatravir prodrug BRII-732.

After completing this activity, participants will be better equipped to discuss the major difficulties in managing MDR HIV and to illustrate the promise of both existing and forthcoming MDR HIV medicines.

“The original misnomer for HIV—gay-related immune deficiency (GRID)—looms large in the consciousness of many gay men and offers a cautionary lesson for monkeypox and other infectious disease outbreaks.”